Close the sale of the Baltimore-Camden manufacturing facility to Bora Pharmaceuticals
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 20 Jun 2024
- Due
- 30 Sep 2024
- Delivered
- 20 Aug 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The agreement includes a transfer of assets, equipment, and workforce associated with the Baltimore-Camden facility, and is expected to close in the third quarter of 2024”
What we found
Evidence strength A What the grades mean
Emergent BioSolutions completed the sale of its Baltimore-Camden drug product facility to Bora Pharmaceuticals on August 20, 2024, which is within the third quarter of 2024.
-
A Emergent BioSolutions Inc. 10-Q filed 2024-11-07
“on August 20, 2024, pursuant to the previously announced Asset Purchase Agreement (the “Asset Purchase Agreement”), the Company completed the sale of its Drug Product facility in Baltimore-Camden (the “Camden Transaction”) to Bora Pharmaceuticals Injectables Inc.” ✓ confirmed on the page
Market reaction: the shares moved +28.8% against the S&P 500 over the three sessions around the disclosure (6 Nov 2024 to 11 Nov 2024). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Acquisition close
- Indicative materiality
- High rules
- Action
- Close
- Deliverable
- Sale of Baltimore-Camden manufacturing facility
- Where
- Baltimore, Maryland
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
- Conditional
- Yes: subject to the satisfaction or waiver of customary closing conditions
- Depends on
- Counterparty
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Emergent BioSolutions Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-EBS-002492 · Corrections policy